NCT00651846 - Investigate Impact of Yasmin vs Microgynon on Hemostasis Parameters in Healthy Women | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

February 28, 2005

Conditions

Healthy

Interventions

DRUG

Yasmin (DRSP 3mg/EE 0.03 mg)

The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).

DRUG

Microgynon (LNG 0.15 mg/EE 0.03 mg)

The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).

Trial Locations (1)

10115

Berlin